Neoadjuvant Tislelizumab Combined with Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Study and Exploration of Immunologic Features

被引：0

作者：

Jin, P. ^{[1
]}

Gao, Y. ^{[1
]}

Fu, Z. ^{[1
]}

Yang, W. ^{[1
]}

Meng, X. ^{[2
]}

机构：

[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China

[2] Shandong Canc Hosp & Inst, Jinan, Peoples R China

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3003

引用

页码：E454 / E454

页数：1

共 50 条

[41] Clinical/biomarker data for neoadjuvant tislelizumab (TIS) plus chemotherapy (Chemo) in resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A single-arm, phase II trial
Li, Q.
Cai, L.
Kuang, D.
Pan, C.
Zhao, J.
Huang, P.
He, C.
Xu, K.
Liu, D.
Long, G.
Liu, Z.
Hu, G.
Lu, X.
ANNALS OF ONCOLOGY, 2024, 35 : S621 - S622
[42] Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.
Dai, Liang
Wu, Yaya
Tian, Ziqiang
Ma, Jianqun
Zhao, Changhong
Zhuang, Bo
Chen, Keneng
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[43] Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma - A single institutional study
Lee, JL
Kim, SB
Jung, HY
Park, SI
Kim, DK
Kim, JH
Song, HY
Kim, WK
Lee, JS
Min, YI
ACTA ONCOLOGICA, 2003, 42 (03) : 207 - 217
[44] Comment on 'Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)'
Cao, Meili
INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (04) : 1060 - 1061
[45] Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study
Liang, Haifeng
Liang, Wenting
Tian, Jiawang
Zheng, Shibei
Su, Yangzhou
Huang, Piao
Chen, Renhui
Guan, Zhong
Cai, Qian
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)
[46] Adjuvant chemoradiotherapy (CRT) plus pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) with high risk of recurrence after neoadjuvant CRT plus surgery: A single-arm phase II study
Guo, Jhe-Cyuan
Huang, Ta-Chen
Kuo, Hung-Yang
Lin, Chia-Chi
Hsu, Feng-Ming
Cheng, Jason C.
Huang, Yen-Lin
Hsieh, Min-Shu
Huang, Pei-Ming
Lee, Jang-Ming
Wu, Shu-Ling
Hsu, Chih-Hung
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 320 - 320
[47] Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
Zhang, Zhi
Ye, Jinjun
Li, Hui
Gu, Dayong
Du, Mingyu
Ai, Dashan
Chen, Wei
Fang, Ying
Xu, Xinyu
Bai, Chenguang
Zhao, Kuaile
Zhou, Guoren
FRONTIERS IN IMMUNOLOGY, 2022, 13
[48] Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A prospective, single-arm, phase II trial
Li, M.
Qu, S.
Lan, G.
Shi, M.
Wang, Y.
Ban, M.
Weng, J.
Wei, J.
Huang, W.
Gui, Z.
Mao, X.
Huang, X.
Xie, S.
Wang, H.
Huang, B.
Qin, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S632 - S632
[49] A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
Chen, Rui
Liu, Qianwen
Li, Qiaoqiao
Zhu, Yujia
Zhao, Lei
Liu, Shiliang
Chen, Baoqing
Liu, Mengzhong
Hu, Yonghong
Lin, Ting
Li, Jibin
Chen, Jiyang
Lv, Yingxin
Fu, Jianhua
Xi, Mian
Yang, Hong
ECLINICALMEDICINE, 2023, 62
[50] Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase., single-arm, exploratory research.
Ma, Jianqun
Zhang, Jinfeng
Yang, Yingnan
Zheng, Dayong
Wang, Xiaoyuan
Liang, Hao
Zhang, Luquan
Xin, Yanzhong
Ling, Xiaodong
Fang, Chengyuan
Jiang, Hao
Zheng, Wei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →